Rapport Therapeutics (RAPP) Competitors $10.88 +0.66 (+6.50%) As of 09:42 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RAPP vs. EVO, IMCR, MESO, VERA, DYN, GPCR, ADPT, ANIP, SPRY, and CALTShould you be buying Rapport Therapeutics stock or one of its competitors? The main competitors of Rapport Therapeutics include Evotec (EVO), Immunocore (IMCR), Mesoblast (MESO), Vera Therapeutics (VERA), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), Adaptive Biotechnologies (ADPT), ANI Pharmaceuticals (ANIP), ARS Pharmaceuticals (SPRY), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry. Rapport Therapeutics vs. Evotec Immunocore Mesoblast Vera Therapeutics Dyne Therapeutics Structure Therapeutics Adaptive Biotechnologies ANI Pharmaceuticals ARS Pharmaceuticals Calliditas Therapeutics AB (publ) Evotec (NASDAQ:EVO) and Rapport Therapeutics (NASDAQ:RAPP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, community ranking, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations. Does the MarketBeat Community believe in EVO or RAPP? Evotec received 4 more outperform votes than Rapport Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Rapport Therapeutics an outperform vote while only 53.85% of users gave Evotec an outperform vote. CompanyUnderperformOutperformEvotecOutperform Votes753.85% Underperform Votes646.15% Rapport TherapeuticsOutperform Votes375.00% Underperform Votes125.00% Which has preferable valuation & earnings, EVO or RAPP? Rapport Therapeutics has lower revenue, but higher earnings than Evotec. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvotec$788.22M1.82-$90.82MN/AN/ARapport TherapeuticsN/AN/A-$34.79M-$3.45-3.15 Do insiders & institutionals believe in EVO or RAPP? 5.8% of Evotec shares are held by institutional investors. 1.0% of Evotec shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media prefer EVO or RAPP? In the previous week, Rapport Therapeutics had 1 more articles in the media than Evotec. MarketBeat recorded 2 mentions for Rapport Therapeutics and 1 mentions for Evotec. Rapport Therapeutics' average media sentiment score of 1.26 beat Evotec's score of 1.20 indicating that Rapport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rapport Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate EVO or RAPP? Evotec presently has a consensus target price of $5.93, indicating a potential upside of 46.86%. Rapport Therapeutics has a consensus target price of $32.67, indicating a potential upside of 200.13%. Given Rapport Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Rapport Therapeutics is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evotec 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Rapport Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is EVO or RAPP more profitable? Company Net Margins Return on Equity Return on Assets EvotecN/A N/A N/A Rapport Therapeutics N/A N/A N/A SummaryRapport Therapeutics beats Evotec on 7 of the 11 factors compared between the two stocks. Get Rapport Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPP vs. The Competition Export to ExcelMetricRapport TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$391.81M$6.54B$5.42B$8.48BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-3.119.1426.7820.05Price / SalesN/A255.59395.49116.44Price / CashN/A65.8538.2534.62Price / BookN/A6.546.874.61Net Income-$34.79M$143.51M$3.22B$248.19M7 Day Performance13.02%5.60%5.69%2.56%1 Month Performance4.86%10.06%12.66%16.18%1 Year PerformanceN/A-0.86%18.01%8.16% Rapport Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPPRapport Therapeutics1.8086 of 5 stars$10.88+6.5%$32.67+200.1%N/A$391.81MN/A-3.11N/APositive NewsEVOEvotec1.5296 of 5 stars$4.17-3.0%$5.93+42.3%-21.9%$1.48B$788.22M0.004,200Positive NewsIMCRImmunocore2.9533 of 5 stars$29.54+4.0%$58.13+96.8%-39.1%$1.48B$310.20M-31.09320Positive NewsMESOMesoblast1.8699 of 5 stars$11.35+3.5%$18.00+58.6%+57.9%$1.45B$5.67M0.0080Gap UpVERAVera Therapeutics3.4019 of 5 stars$22.49+3.6%$63.33+181.6%-48.2%$1.43BN/A-8.6240Positive NewsDYNDyne Therapeutics3.7986 of 5 stars$12.56+10.1%$46.85+273.0%-65.1%$1.43BN/A-3.53100Positive NewsHigh Trading VolumeGPCRStructure Therapeutics2.1536 of 5 stars$24.62-3.7%$78.00+216.8%-31.1%$1.41BN/A-33.27136ADPTAdaptive Biotechnologies3.6065 of 5 stars$9.51+5.3%$9.83+3.4%+160.7%$1.37B$189.53M-8.72790News CoveragePositive NewsANIPANI Pharmaceuticals4.8525 of 5 stars$62.30-6.0%$80.13+28.6%-1.8%$1.36B$614.38M-113.27600Positive NewsHigh Trading VolumeSPRYARS Pharmaceuticals2.4629 of 5 stars$13.29-1.1%$31.00+133.3%+55.9%$1.31B$89.15M-26.0690Trending NewsEarnings ReportAnalyst RevisionCALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180 Related Companies and Tools Related Companies EVO Competitors IMCR Competitors MESO Competitors VERA Competitors DYN Competitors GPCR Competitors ADPT Competitors ANIP Competitors SPRY Competitors CALT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RAPP) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
